Avantect® Pancreatic Cancer Test
When risk is elevated, clarity matters
Early detection may make all the difference
The stage of pancreatic cancer at diagnosis has a significant impact on survival.1 Pancreatic cancer diagnosed at its earliest stage (IA) improves the expected 5-year survival rate to approximately 80%.2 With the disease projected to become the second leading cause of cancer death by 2030, earlier detection is key to improving outcomes.3
5-year survival of >80% for Stage IA pancreatic cancer2
Get started with Avantect
Get started with Avantect
The Avantect Pancreatic Cancer Test is a multiomics blood-based test that evaluates multiple biologically relevant cancer associated signals. For individuals at elevated risk for pancreatic cancer, Avantect provides actionable insights designed to help inform what comes next – supporting earlier navigation of care.
A breakthrough innovation for elevated pancreatic cancer risk
Epigenetic changes are present in the earlier stages of pancreatic cancer. Chemical modifications of DNA such as 5-hydroxymethylcytosine (5hmC) have now been identified as powerful biomarkers for pancreatic cancer.
The Avantect Pancreatic Cancer Test is a multiomics assay that combines epigenomic 5hmC patterns, genomic features, and glycan biomarker measurements, analyzed through optimized machine learning algorithms, to generate a single blood-based result designed to identify pancreatic cancer signals at early stages of disease.5,6,7
Epigenetic changes are present in the earlier stages of pancreatic cancer. Chemical modifications of DNA such as 5-hydroxymethylcytosine (5hmC) have now been identified as powerful biomarkers for pancreatic cancer.
The Avantect Pancreatic Cancer Test is a multiomics assay that combines epigenomic 5hmC patterns, genomic features, and glycan biomarker measurements, analyzed through optimized machine learning algorithms, to generate a single blood-based result designed to identify pancreatic cancer signals at early stages of disease.5,6,7
For individuals at elevated risk for pancreatic cancer
For individuals at elevated risk for pancreatic cancer
Know their risk. Know their options.
Certain clinical and inherited factors are recognized as purple flags associated with elevated pancreatic cancer risk. Avantect is designed for individuals with one or more of these risk factors.
Know their risk. Know their options.
Certain clinical and inherited factors are recognized as purple flags associated with elevated pancreatic cancer risk. Avantect is designed for individuals with one or more of these risk factors.
Family History
of pancreatic cancer
Relative Risk: 4 – Over 9x 8,9,10
Relative Risk: 4 – Over 9x 8,9,10
Genetic Predisposition
BRCA1, BRCA2, ATM, MLH1, MSH2, MSH6, EPCAM, CKDN2A, PRSS1, SPINK1, or STK11 / LKB1
Relative Risk: 2.3 – Over 30x 9
Relative Risk: 2.3 – Over 30x 9
New-onset Diabetes
in adults over age 50
Relative Risk: 6 – 8x 11,12,13
Relative Risk: 6 – 8x 11,12,13
Unsurpassed accuracy in pancreatic cancer detection
Clear, confident insights to help guide what comes next.
Clinically validated to deliver strong overall and early-stage sensitivity with high specificity, Avantect supports confident next-step decisions in elevated-risk care based on a validation study versus case-control study of pancreatic cancer patients (n=259) and non-cancer subjects (n=1,186).14
Clear, confident insights to help guide what comes next.
Clinically validated to deliver strong overall and early-stage sensitivity with high specificity, Avantect supports confident next-step decisions in elevated-risk care based on a validation study versus case-control study of pancreatic cancer patients (n=259) and non-cancer subjects (n=1,186).14
Why Choose Avantect
Designed to help inform next-step discussions
Provide complementary information that may be considered with other clinical findings when discussing whether further evaluation or continued surveillance may be appropriate.
Provide additional context in elevated risk
Offer additional information to be considered alongside other clinical findings, with next-step decisions determined by the healthcare provider.
Enable informed, shared decision-making
Support clear conversations between patients and healthcare providers by presenting results in a straightforward, easy-to-understand report format.
Why Choose Avantect
Designed to help inform next-step discussions
Provide complementary information that may be considered with other clinical findings when discussing whether further evaluation or continued surveillance may be appropriate.
Provide additional context in elevated risk
Offer additional information to be considered alongside other clinical findings, with next-step decisions determined by the healthcare provider.
Enable informed, shared decision-making
Support clear conversations between patients and healthcare providers by presenting results in a straightforward, easy-to-understand report format.
Easy to order. Designed for clarity
The Avantect test is easily incorporated into clinical management protocols for patients you know to be at high risk for pancreatic cancer. A simple blood draw can provide life-changing information.
Request a collection kit
Collect and ship sample
Test results delivered in 14 days
Important information
The Avantect Pancreatic Cancer Test is an early detection test. The test does not establish a diagnosis of pancreatic cancer, and results should be considered in the context of other clinical criteria. Definitive diagnosis of pancreatic cancer usually requires a series of imaging scans, blood tests, and a biopsy. Not all pancreatic cancers will be detected. Some patients with pancreatic cancer may have a “Pancreatic Cancer Signal not detected” result. Some patients without pancreatic cancer may have a “Pancreatic Cancer Signal detected” result. False-negative and false-positive results are possible. A “Signal not detected” result does not guarantee that no pancreatic cancer is present. In some cases, no result is obtained. While this is very uncommon, it may be caused by shipping delays or when there is not enough cell-free DNA for the test in the patient’s blood. If this happens, we generally ask for a repeat blood sample for testing at no extra cost.
The test was developed in the ClearNote Health CLIA-certified (CLIA# 05D2249973) and CAP-accredited (CAP# 9219174) laboratory and has not been cleared or approved by the US Food and Drug Administration (FDA).
References and notes
- Cancer Stat Facts: Pancreatic Cancer. (Accessed 2/6/2026, at https://seer.cancer.gov/statfacts/html/pancreas.html)
- Blackford AL, Canto MI, Klein AP, Hruban RH, Goggins M. Recent trends in the incidence and survival of stage 1A pancreatic cancer: a surveillance, epidemiology, and end results analysis. J Natl Cancer Inst. 2020;112(11):1162-1169.
- https://pancan.org/pressreleases/pancreatic-cancer-deaths-continue-to-rise-five-year-survival-rate-remains-stalled-at-13-while-all-cancers-combined-reach-milestone-70/#:~:text=Pancreatic%20Cancer%20Action%20Network%20Calls,treatment%20options%2C%20and%20research%20investment
- Pereira SP, Oldfield L, Ney A, Hart PA, Keane MG, Pandol SJ, Li D, Greenhalf W, Jeon CY, Koay EJ, Almario CV, Halloran C, Lennon AM, Costello E. Early detection of pancreatic cancer. Lancet Gastroenterol Hepatol. 2020 Jul;5(7):698-710.
- Guler GD, Ning Y, Ku CJ, et al. Detection of early stage pancreatic cancer using 5-hydroxymethylcytosine signatures in circulating cell free DNA. Nat Commun 2020;11:5270.
- Haan D. In Preparation-Validation of a Blood-Based Early Detection Test for Pancreatic Cancer. Bluestar Genomics; 2022.
- Chowdhury S, Kesling M, Collins M, et al. Analytical Validation of an Early Detection Pancreatic Cancer Test Using 5-Hydroxymethylation Signatures. J Mol Diagn 2024;26:888-96.
- Klein AP. Genetic susceptibility to pancreatic cancer. Mol Carcinog 2012;51:14-24.
- NCCN. Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic Version 3.2025.
- Aslanian HR, Lee JH, Canto MI. AGA Clinical Practice Update on Pancreas Cancer Screening in High-Risk Individuals: Expert Review. Gastroenterology 2020;159:358-62.
- Chari ST, Leibson CL, Rabe KG, et al. Pancreatic cancer-associated diabetes mellitus: prevalence and temporal association with diagnosis of cancer. Gastroenterology 2008;134:95-101.
- Chari ST, Wu B, Lopez C, et al. Risk of Pancreatic Cancer in Glycemically Defined New-Onset Diabetes: A Prospective Cohort Study. Gastroenterology 2025.
- Sharma A, Kandlakunta H, Nagpal SJS, et al. Model to Determine Risk of Pancreatic Cancer in Patients With New-Onset Diabetes. Gastroenterology 2018;155:730-9 e3.
- Data on file.